LUMINOR FEATURES
Approved for all indications
Luminor is indicated to use in iliac, femoropopliteal, infrapopliteal and renal arteries stenosis and for AV fistula.
Brings complete portfolio
Luminor is available with the 3 guidewire compatibilities (0.014", 0.018" and 0.035") to adapt to the necessities of each procedure
Benefits with the procedure
- Small profile
- good pushability and trackability
- Short deflation times
NOT ALL DCB ARE SAME
Coating technology
- TransferTech, the iVascular proprietary nanotechnology that Has an ultrathin coating thanks to the nanodrop technology used to coat the balloons.
- Ensures a durable coating due to its multilayer technology, with minimum drug loss during navigation.
- Ensures a uniform artery treatment.
Formulation
Ensure low drug loss, quick transfer and more retention time in the artery:
- 20% excipient
- 80% paclitaxel
Spray NanoTechnology
Ultrasound pule to break the solution into uniform nanodrops
Spray dosage system that provides a homogenous drug distribution.
Ultra thin multilayer coating
Minimizes drug loss while navigating to the lesion, reduce the coating stress and the risk of cracking.
Dry-off technology
Process to create paclitaxel microcrystals, which can be transferred fast and maintain more time.
CLINICAL SUPPORT
Description
- Device: Luminor 35
- Number of patients: 171
- Followup: 5 years
- Type of Lesions: Femoropopliteal arteries, lesions TASC A&B
Conclusion: The innovative coating technique matters and is shown not only in the patency, LLL and TLR data, but also in the safety outcomes. The results of the study allow direct comparison to other already-completed RCTs applying DCB from different manufacturers in the same target vessels.
EffPac 5-year has been presented at LINC 2022 by Prof Ulf Teichgräber.
Main Investigator: Prof. U. Teichgräber Hospital University of Jena (Jena, DE)
Description
- Device: Luminor 18, Luminor 35 and iVolution pro
- Number of patients: 100
- Followup: 5 years
- Type of Lesions: Long femoropopliteal lesions TASC C&D
In conclusion, Dr. Koen Deloose stated that “the combined use of Luminor and iVolution pro seems to be, in the longer run, the perfect solution for complex lesion treatment”.
Main Investigator: Dr. Koen Deloose, A.Z, Sint-Blasius Hospital (Dendermonde, BE)
Description
- Device: Luminor 14m & Angiolite BTK as bailout stenting
- Number of patients: 50
- Followup: 2 years
- Type of Lesions: Long tibial occlusive lesions TASC C&D
Luminor DCB is safe and efficacious, in treating highly complex infra-popliteal atherosclerotic lesions in challenging CLTI patients. Luminor is associated with highly satisfactory acute technical success, 6-month target lesion patency and AFS.
Main Investigator: Dr T. Tang, General Hospital (Singapore)